CJC-1295 DAC vs PEG-MGF.

CJC-1295 with DAC (also written DAC:GRF, CJC-1295 DAC) is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). It is built on the bioactive N-terminal GHRH(1-29) fragment with several amino-acid substitutions, plus a "Drug Affinity Complex" (DAC): a maleimidopropionyl group that lets the peptide bind covalently to circulating albumin after injection. It was developed in the mid-2000s by ConjuChem Biotechnologies as an investigational drug; it is not an approved medicine and today circulates mainly as a research/gray-market peptide.

PEG-MGF is a PEGylated synthetic peptide based on the unique C-terminal E-domain of mechano growth factor (MGF), an alternatively spliced isoform of insulin-like growth factor-1 known as IGF-1Ec (the rodent equivalent is IGF-1Eb). MGF is produced locally by skeletal muscle in response to mechanical loading or damage; the research peptide reproduces its distinctive 24-amino-acid E-peptide rather than the full IGF-1 molecule. The polyethylene glycol (PEG) moiety is a chemical modification intended to slow degradation of the otherwise very short-lived native peptide. It is a research-use-only chemical, not an approved drug.

Like native GHRH, CJC-1295 binds the GHRH receptor on anterior pituitary somatotrophs and stimulates synthesis and pulsatile release of growth hormone (GH), which in turn drives hepatic and peripheral IGF-1 production. Two engineering features extend its action: amino-acid substitutions in the GHRH(1-29) backbone resist cleavage by dipeptidyl-peptidase-4 (DPP-4), and the DAC maleimide group forms a covalent bond with cysteine-34 of serum albumin, shielding the peptide from renal filtration and proteolysis so it persists in plasma for days rather than minutes. Because it amplifies the body's own GH axis rather than supplying exogenous GH, secretion remains somewhat pulsatile and subject to negative feedback (e.g., somatostatin).

Native MGF arises when the IGF-1 gene is alternatively spliced after mechanical stress, producing a transcript whose distinct C-terminal "E-domain" differs from the IGF-1Ea isoform. The Goldspink group's central proposal, supported by cell-culture work, is that the MGF E-peptide acts to expand the pool of muscle satellite (stem) cells by promoting myoblast proliferation while delaying their differentiation, whereas mature IGF-1 drives differentiation and protein synthesis through the IGF-1 receptor (Yang & Goldspink, FEBS Lett 2002). Notably, several studies report that the isolated E-domain peptide exerts effects that do not appear to require classical IGF-1 receptor binding, implying a separate, still incompletely defined receptor/signaling pathway. PEGylation is intended only to lengthen circulating half-life and does not change this proposed biology.

Human evidence comes mainly from early-phase ConjuChem trials in healthy adults. Teichman et al. (JCEM, 2006) reported that single subcutaneous doses produced dose-dependent, sustained elevations of GH and IGF-1, with IGF-1 remaining above baseline for several days and repeated weekly/biweekly dosing maintaining elevated IGF-1. Ionescu and Frohman (JCEM, 2006) showed that despite continuous GHRH-receptor stimulation, GH secretion remained pulsatile in healthy men. Preclinical support includes Alba et al. (Am J Physiol Endocrinol Metab, 2006), where once-daily CJC-1295 normalized growth in GHRH-knockout mice, and Sackmann-Sala et al. (Growth Horm IGF Res, 2009), which characterized GH/IGF-1-axis-driven serum protein changes. Crucially, there are no published controlled trials demonstrating clinical outcomes (body composition, strength, fat loss, anti-aging, or healing) in humans; the human data establish a pharmacodynamic GH/IGF-1 effect, not proven therapeutic benefit, and the program was discontinued without an approved indication.

The human evidence base for PEG-MGF specifically is essentially absent: no completed human clinical trials evaluating the PEGylated peptide for any indication could be identified. The underlying MGF biology rests on preclinical and ex vivo work, much of it from Geoffrey Goldspink's UCL group: mechanical stretch and stimulation induce an IGF-1 splice variant in rabbit and rodent muscle (Yang et al., J Physiol 1999; Hill & Goldspink, J Physiol 2003), the MGF E-peptide and mature IGF-1 play distinct proliferation-vs-differentiation roles in cultured myoblasts (Yang & Goldspink, FEBS Lett 2002), and a synthetic MGF E-peptide can act through a mechanism distinct from the IGF-1 receptor (Mills et al., 2007) and improve myogenic precursor cell transplantation in animals (Am J Transplant 2007). Animal studies have also explored MGF in acute myocardial infarction (Carpenter et al., Heart Lung Circ 2008) and neuronal injury models. These data establish biological plausibility for muscle repair signaling but do not demonstrate safety or efficacy of PEG-MGF in humans, and findings in cell/animal systems frequently fail to translate.

In the short early-phase human studies, the most consistently noted effects were injection-site reactions and transient flushing; sustained IGF-1 elevation also raises theoretical concerns common to GH-axis stimulation, such as fluid retention, joint discomfort, carpal-tunnel-type symptoms, and reduced insulin sensitivity. Long-term human safety is essentially uncharacterized: no large or long-duration controlled trials were completed, and chronically elevated GH/IGF-1 is a biologically plausible (though unproven for this compound) concern for promoting growth of existing neoplasms. Real-world risk is compounded by the fact that material sold as "CJC-1295 DAC" is unregulated and may vary in purity, identity, or sterility. No dosing or administration guidance is provided here.

There is no human safety data for PEG-MGF; it has not undergone formal toxicology or clinical evaluation, so its adverse-effect profile, immunogenicity, and long-term risks in people are unknown. As a peptide in the IGF-1 family that promotes cell proliferation, a theoretical concern is unwanted stimulation of growth in non-target or abnormal tissues, though this has not been characterized for this molecule. PEGylated therapeutics as a class can elicit anti-PEG antibodies and, rarely, injection-site or hypersensitivity reactions, but whether this applies to PEG-MGF is unstudied. Research-grade material also carries quality, purity, and contamination uncertainties because it is not manufactured to pharmaceutical standards.

CJC-1295 (with or without DAC) is not approved by the FDA or any major regulator for any use; clinical development was discontinued and it is treated as an unapproved/investigational substance, with U.S. authorities also flagging it as unsuitable for pharmacy compounding. It is prohibited in sport at all times by the World Anti-Doping Agency as a GH-releasing factor under Category S2 of the Prohibited List.

PEG-MGF is not approved by the FDA or any major regulatory agency for any use and is sold only as a research-use-only chemical, not for human consumption. The mechano growth factor E-domain peptide is prohibited in sport: WADA lists growth factors affecting muscle, including MGF, under category S2 (peptide hormones, growth factors, related substances).